China: The China Drug Administration Proposes A Working Procedure For Pharmaceutical Study Data Protection

Last Updated: 9 May 2018
Article by Katherine Wang

In response to the central government’s calling for a data protection mechanism,1 the China Drug Administration (the “CDA”) published a draft on Implementing Measures for Pharmaceutical Study Data Protection (the “Draft”) on April 25, 2018 for public comments. This Draft specifies data protection scope, extends the data protection period, and, for the first time, proposes a working procedure for applying for and granting a data protection right.

To Redefine Protection Scope

Since China’s entry to the WTO in 2002, drugs containing innovative chemical entities have been entitled to six years of data exclusivity protection.2 The Draft expands the protection scope to cover both innovative drugs and generic drugs. Specifically, eligible drugs include (i) innovative drugs, (ii) innovative therapeutic biologics, (iii) orphan drugs, (iv) pediatric drugs, and (v) generic drugs to which pertinent patents have been invalidated.

The current data protection mechanism protects independently generated and undisclosed study data and other data. The Draft narrows the scope of protected data to those independently generated and undisclosed non-clinical and clinical study data that is submitted for marketing authorization purposes only if they are related to product efficacy. Product safety data in the regulatory submissions is excluded from protection.

To Extend Protection Period

The Draft offers a variety of protection periods up to 12 years (for details, please see the table below). The level of protection is on par with what the USFDA offers3 and surpasses what the EMEA provides.4


Protection Period

Innovative drugs

6 years from the date of marketing authorization in China

Innovative therapeutic biologics

12 years from the date of marketing authorization in China

Orphan drugs

6 years from the date of the first approval of the relevant indication in China

Pediatric drugs

6 years from the date of the first approval of the relevant indication in China

Generic drugs to which pertinent patents have been invalidated (i.e., first-to-market generics)


To incentivize early launches of new drugs in China, the protection period for an innovative drug will be reduced by one to five years if the New Drug Approval (NDA) application is first filed outside China in reliance of data from multi-regional clinical studies on Chinese patients. No protection will be granted if such NDA application is filed six years later than the first foreign filing. Further, a protection period will be reduced (i) by 75% if a NDA application is solely based on overseas clinical data or (ii) by 50% if such NDA application is based on supplemental studies on Chinese subjects.

To Provide an Implementing Mechanism

The Draft introduces a working procedure for pharmaceutical companies to apply for and exercise its data protection right. An NDA applicant can apply for a study data protection right in the NDA application with the CDA. The CDA may grant a data protection right together with the relevant NDA. Information about the rationale for data protection and its exclusivity term will be publically available in China’s Orange Book.

If any subsequent application concerns a drug having the same active ingredient and indication as that of a protected drug during the exclusivity term, the CDA will notify the relevant data protection right owner within 30 days after its receipt of the application. The right owner can oppose this application within 30 days after receiving the notification. If the right owner opposes, the CDA will verify and decide on the authenticity of the data submitted by the other applicant, e.g., whether this data is truly independently generated by the applicant or from properly authorized sources. Either the right owner or the applicant can appeal to the CDA’s decision by administrative appeals or litigations.

To Prevent Abuse of Right

The Draft requires a data protection right owner to voluntarily disclose its protected data after the right is conferred. However, it is unclear whether the right owner is obligated to disclose any protected data that contains trade secrets or personal data.

In addition, an approved data protection right can be revoked by the CDA upon a third-party request if the relevant right owner fails to market and sell the protected drug within one year after receiving the NDA.

The updated regulatory data protection mechanism is encouraging, but several questions remain unclarified, for example, how an innovative drug is defined; which types of patents, if being successfully challenged, can render a generic drug eligible for data protection; the exclusivity term of first to market generics; and the definition of “independently generated data,” etc. We advise that pharmaceutical companies submit comments to the CDA by May 31, 2018.


1 See the General Office of the CPC Central Committee and the General Office of the State Council’s Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices dated October 2017.

2 See Article 34 of the Implementing Regulation of the Drug Administration Law (2016) and Article 20 of the Drug Registration Administration Measures (2007).

3 The U.S. grants a maximum 12 years of data protection period to biologics.

4 The EU grants a maximum 10 years of data protection period to innovative drugs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions